Grant ID

98-RC-301-6

Illness

Bipolar Disorder

Primary Drug/Intervention

Topiramate

Primary Dosage

N/A

Secondary Drug Intervention

Lithium

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Rush

Sample Size

40

Duration of Study Period for Each Subject

N/A

Outcome Measurements

N/A

Results

40 subjects ages 7-17 with bipolar I or II disorder treated with 1 or 2 of (DVP, Li, quetiapine, risperodone and olanzepine) are treated in an 8 week dould-blind placebo controlled trial with adjunctive topiramate. An open label 8 week extension phase to ensure that subjects all have potential benefit from the research.

Publication

N/A

Link

N/A

PI Name

John Rush

Degree

MD

Center

UT Southwestern Medical Center

Institution

N/A

Address

City or Town

Dallas

State or Province

TX

Zip or Postal Code

N/A

Country

USA

Email Address

john.rush@utsouthwestern.edu